Alota, Jhaydeil A.
HRN: 23-12-81 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2023
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
06/02/2023
06/08/2023
PO
7.5ml
Q12
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes